Overview Faculty & Disclosures Agenda Sheraton Grand Chicago Registration
Live Simulcast Educational Needs Target Audience Learning Objectives CME/CE Credit Information
Symposium Registration is now open · Register Early
Epidermal Growth Factor Receptor for Non-Small Cell Lung Cancer 3.0 - GREAT DEBATES - CLINICAL CASES - EXPERT PANELS
6:00PM Registration and Light Dinner
7:00PM Welcome, Introductions and CME/CE Pre Test
Dr. Riely
7:10PM DEBATE 1: Are There Differences Between First- and Second-Generation EGFR-directed Therapies?
  • There are meaningful differences among the first and second-generation EGFR TKIs- Dr. West
  • First- or second-generation EGFR inhibitor TKIs are interchangeable - Dr. Kelly
Dr. West vs. Dr. Kelly
7:30PM Q&A and Interactive Panel Discussion and Answering Queued-up Audience Questions
Dr. Riely
7:40PM Targeting T790M Mutation Positive patients: Clinical developments, challenges and opportunities, including efficacy and toxicity issues
Dr. West
7:55PM Targeting T790M Mutation Negative patients: Clinical developments, challenges and opportunities, including efficacy and toxicity issues
Dr. Wakelee
8:10PM EGFR TKIs in Wild Type Patients: Significant differences? Meaningful benefits?
Dr. Riely
8:30PM DEBATE 2: Tissue Versus Liquid Biopsies to Assess Resistance to EGFR TKIs.
  • Liquid biopsies can sufficiently assess the mechanisms of resistance to EGFR TKIs - Dr. Wakelee
  • Tissue biopsies are the gold standard and cannot yet be replaced - Dr. Scagliotti
Dr. Wakelee vs. Dr. Scagliotti
8:50PM Q&A and Interactive Panel Discussion and Answering Queued-up Audience Questions
Dr. Scagliotti
9:00PM Closing Remarks CME/CE Post Test and Adjourn
Dr. Scagliotti
Overview Back to top
Co-Chairs: Drs. Gregory Riely and Giorgio Scagliotti

The objective of this symposium is to help medical oncologists and other Health Care Professionals (HCPs) understand how to best utilize all three generations of EGFR-directed therapy for NSCLC patients. This includes how to determine the optimal use of each of the three generations of EGFR-directed therapies for specific NSCLC patients based upon the latest data involving various EGFR mutations. In addition, all of the other major variables will be addressed such as optimal sequencing of therapies, single-versus combination therapy, and the use of liquid versus tissue serial biopsies as tools to help guide when EGFR therapy should be changed for a particular patient. This symposium provides CME credit to physicians, CNE credit to nurses, CPE credit to pharmacists and a Certificate of Attendance for fellows, and all other HCPs.

Bring your own Smartphones, Tablets, or Laptops
(iPad, Android, iPhone, etc.): This will enable participants to use their personal "smart devices" during the symposium to ask and answer all questions of the faculty.

This activity is being hosted in association with GRACE
Faculty & Disclosures Information Back to top
Gregory J. Riely, MD, PhD (Co-Chair)
Medical Oncologist, Thoracic Oncology Service
Vice Chair, Clinical Trials Office
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Consulting Fees: Genentech/Roche
Contracted Research: Roche, Millennium, Pfizer, Novartis

Giorgio V. Scagliotti, MD, PhD (Co-Chair)
Head, Thoracic Oncology Unit
Department of Clinical and Biological Sciences
University of Turin
San Luigi Hospital
Orbassano, Italy

Consulting Fees: Eli Lilly, AstraZeneca, Roche, Clovis Oncology
Fees for Non-CME/CE Services Received Directly from Commerical Interest or Their Agents (e.g. speakers’ bureaus): Eli Lilly, AstraZeneca

Karen Kelly, MD
Associate Director for Clinical Research
Professor of Medicine
Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon,
Endowed Chair in Cancer Clinical Research
UC Davis Comprehensive Cancer Center
Sacramento, CA

Royalty: UptoDate On-Line Physician Resource Author
Consulting Fees: Synta, Lilly, Clovis, Genentech, AstraZeneca, Ariad, Boehringer Ingelheim
Contracted Research: Millennium, Novartis, EMD Serono, Lilly, Genentech, AbbVie, Giliead, Celgene

I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

Howard "Jack" West, MD
Medical Director
Thoracic Oncology Program
Swedish Cancer Institute
President and CEO
Global Resource for Advancing Cancer Education
Seattle, WA

Consulting Fees: AstraZeneca, Boehringer Ingelheim, Genentech/Roche, Guardant Health
Fees for Non-CME/CE Services Received Directly from Commerical Interest or Their Agents (e.g. speakers’ bureaus): Genentech/Roche

Heather A. Wakelee, MD
Assistant Professor
Department of Medicine
Division of Oncology
Stanford Cancer Institute
Stanford Comprehensive Cancer Center
Stanford, CA

Consulting Fees: Peregrine, ACEA, Pfizer, Helsinn
Contracted Research: Clovis, Exelixis, AstraZeneca/MedImmune, Genentech/Roche, BMS, Gilead, Novartis, Xcovery, Pfizer, Celgene, Pharmacyclics, Lilly

I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

LEAD NURSE PLANNER
Diane D. DePew, DSN, RN-BC

I have no real or apparent conflicts of interest to report.

PLANNER & CME/CE REVIEWER
Steve Madison, RPh, MBA (BMLI Manager)

I have no real or apparent conflicts of interest to report.

CME/CE PEER REVIEWER
Danielle Shafer, MD

I have no real or apparent conflicts of interest to report.

Supported by Educational Grants from Clovis Oncology and Boehringer Ingelheim
Educational Needs Back to top

The educational needs addressed by this symposium are to help medical oncologists and other Health Care Professionals (HCPs) understand how to best utilize all three generations of EGFR-directed therapy for NSCLC patients. This includes how to determine the optimal use of each of the three generations of EGFR-directed therapies for specific NSCLC patients based upon the latest data involving various EGFR mutations. In addition, all of the other major variables will be addressed such as optimal sequencing of therapies, single-versus combination therapy, and the use of liquid versus tissue serial biopsies as tools to help guide when EGFR therapy should be changed for a particular patient.

Target Audience Back to top

This live symposium on June 3, 2016 (including the live “real-time” Internet streaming simulcast} and archived enduring materials for one year) is designed to meet the educational needs of and help close Practice Gaps of medical oncologists, hematologists, radiation oncologists, surgical oncologists, pathologists, oncology pharmacists, oncology nurses/Nurse Practitioners and other allied health-care professionals involved in the treatment, care and management of patients with lung cancer, including physician assistants and fellows. Lung cancer is treated optimally by a multi-disciplinary approach of clinicians and, thus, all of the aforementioned clinician specialties are targeted for invitation to this CME/CE activity for lung cancer patients with EGFR-Positive NSCLC.

Learning Objectives Back to top
PHYSICIAN
  1. Compare and contrast the efficacy, safety, and mechanism of action differences between the first-, second- and third-generation EGFR-directed therapies for EGFR-positive NSCLC patients.
  2. Understand how to use liquid biopsies versus tissue biopsies to optimally sequence EGFR therapies to know when to switch therapies.
  3. Evaluate the pros and cons of using next generation sequencing (NGS) genomic testing panels and their ctDNA liquid biopsy tests.
  4. Analyze EGFR-Treatment-based strategies using monotherapy versus combination therapy for EGFR mutation-positive NSCLC.
NURSE AND PHARMACIST
  1. Recall the efficacy, safety, and mechanism of action differences between the first-, second- and third-generation EGFR-directed therapies for EGFR-positive NSCLC patients.
  2. Review how to use liquid biopsies versus tissue biopsies to optimally sequence EGFR therapies to know when to switch therapies.
  3. List the pros and cons of using next generation sequencing (NGS) genomic testing panels and their ctDNA liquid biopsy tests.
  4. Identify EGFR-Treatment-based strategies using monotherapy versus combination therapy for EGFR mutation-positive NSCLC.
CME/CE Credit Information Back to top

Physicians

The BioMedical Learning Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The BioMedical Learning Institute designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™.

Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacists

The BioMedical Learning Institute is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN: 0838-0000-16-002-L01-P
Credits: 2 hours (0.2 ceus)
Type of Activity: Knowledge

To receive CE contact hour credit, attendance at the entire activity and the successful completion of the post‐test and evaluation form is required.

Nurses

The BioMedical Learning Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The BioMedical Learning Institute designates this educational activity for 2 contact hours.

Accreditation by the American Nurses Credentialing Center's Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

To receive CE contact hour credit, attendance at the entire activity and the successful completion of the post‐test and evaluation form is required.

Other

Physician Assistants: AAPA accepts certificates of attendance for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 2 hours of Category 1 credit for attending this symposium.

Fellows will receive a certificate of attendance that they can submit to their accrediting organizations for continuing education credit.

Sheraton Grand Chicago Back to top

Sheraton Grand Chicago
301 E North Water St
Chicago, IL 60611
Phone: (312) 464-1000

Live Internet Simulcast Back to top

The following are some final details regarding your remote participation via live Internet Video Simulcast in real-time at the forthcoming "Epidermal Growth Factor Receptor and Non-Small Cell Lung Cancer 3.0."

Your Options for participation in the Internet Simulcast
You have 2 ways to participate in this symposium via the Internet Simulcast. Either way will enable you to CME/CE credit.

  • Interactive: One involves interactive participation enabling you ask queued-up questions of the faculty at anytime throughout the symposium just like the participants in the live meeting in Chicago. You can also answer clinical and case study questions from the faculty during each presentation.
  • Non-Interactive: The other way to participate is to simply watch and listen to the symposium without asking or answering questions.

If you choose interactive participation for the symposium, you will need to have two separate internet browser windows open or two separate smart devices. Ideally, you should use your iPhone to ask and answer questions, and your computer or laptop to view the symposium. The symposium will be video broadcast to you with two live cameras feeds. If you use just one smart device, e.g., your computer, please use one browser window to view and hear the symposium presentations live, and the other browser window to ask and answer questions during the symposium. Each browser window connects to a different Web Site.

  • Browser #1 to only view and listen to the symposium please click on the following Web Site hyperlink with your other browser window or iPad, iPhone, etc.: http://www.liveeventstream.com/bmli/bmli.html
  • Browser#2 to ask and answer questions with the faculty: please click on the following Web Site hyperlink with your other browser window or iPad, iPhone, etc.: https://bmli.cnf.io
  • Instructions to use bmli.cnf.io Web Site are here: Instructions

To participate in a non-interactive manner please click on the following Web Site hyperlink: http://www.liveeventstream.com/bmli/bmli.html

Technical Requirements and Testing Your Connections
It is highly recommended you test your Internet connection between 6:00PM to 7:00P Central Time on Friday, June 3, 2016. Our system will be operational during this 60-minute time period which has been dedicated for testing and if you have any questions during this time please use the support chat feature (link to right Web Site) or call the following telephone number: 1-800-209-1868

Minimum Requirements for the Live Internet Simulcast
PC Requirements
You need Windows XP Service Pack 2, Windows Vista, Windows 7 or Windows 8, and you'll need to use Internet Explorer or Firefox for your web browser. You should have at least a 1.2-gigahertz processor and 512 megabytes of RAM. Your Internet connection speed should be at least 1.5 Mbps.
Mac Requirements
You need an Intel-based computer with at least OS 10.4.11 and Firefox 3 or Safari 3. You'll also need at least 1 gigabyte of RAM. Your Internet connection speed should be at least 1.5 Mbps. The Microsoft Silverlight plug-in will be required (it is generally installed on most computers already). You can check here if you have it installed: https://www.microsoft.com/getsilverlight/Get-Started/Install/Default.aspx

Symposium Sessions
The general session of the symposium on Friday, June 3, 2016 is scheduled from at 7:00 p.m. to 9:00 p.m. Central Time. The complete agenda can be viewed at: http://www.bmli.com/live/egfr3/index.php#agenda

CME, CE Certificates, Certificates of Attendance and Completed Symposium Evaluation Forms
In order for you to receive your CME or CE Certificate, or Certificate of Attendance you must complete the evaluation of the symposium and answer a brief knowledge test. This evaluation form and test is only available online at the following Web Site beginning June 3, 2016 until June 17, 2016: https://bmli.cnf.io Fellows may complete a Certificate of Attendance for use in seeking CME credit in their States.

Not an official event of the 2016 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.